Neuro:

General:
- Spectrum of neurological complications following COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8557950/
- Covid Vaccines are not free of Neurologic side effects: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206845/
- COVID-19 mRNA vaccination leading to CNS inflammation: a case series https://link.springer.com/article/10.1007/s00415-021-10780-7?fbclid=IwAR1WIozzELtGyD_DttkLNZFMcl3yW6iBW9COv8uRyiYtTulzRvKVPE_yYko
- Rebuttal about Functional Neurologic Disorders and Vaccination: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26160?fbclid=IwAR3C-QQc-ZDEDoCu0fWNQuVYzvbC3qYHGekCaicU5-1_bOUz4N52j1wji0
- Neurologic safety monitoring of COVID-19 vaccines, lessons learned from the past to inform the present: https://pubmed.ncbi.nlm.nih.gov/34475124/

Neuropathy:
- Small fiber neuropathy: https://onlinelibrary.wiley.com/doi/10.1002/mus.27251...

POTS:
- Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine https://academic.oup.com/ehjcr/article/5/12/ytab472/6444985

Neuralgia - Trigeminal, amyotrophy:
- Neurolgic amyotrophy following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34347105/
- Neurolgic amyotrophy of the lumbosacral plexus following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34816739/
- 2 cases of Parsonage Turner Syndrome following Moderna and Pfizer: https://pubmed.ncbi.nlm.nih.gov/34402669/

Transverse Myelitis:
70yoM with acute autoimmune transverse myelitis following Moderna: https://pubmed.ncbi.nlm.nih.gov/34941191/
Longitudinal extensive transverse myelitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34507942/
Longitudinal extensive transverse myelitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34182207/

GBS:
GBS following 2nd dose of Pfizer: electromyoneurography and laboratory findings: https://pubmed.ncbi.nlm.nih.gov/34347563/
GBS following Pfizer in a 42yoM: https://pubmed.ncbi.nlm.nih.gov/34779385/
GBS in a 42yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34567447/
GBS in a 61yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34484780/
GBS in a 65yoM liver transplant patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34431208/
GBS in a 67yoM following 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34796417/
GBS in a 73yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34477091/
GBS in 73yoM following 2nd dose of Pfizer: https://www.ncbi.nlm.nih.gov/PMC8253659/
GBS in 82yoF following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/33758714/
GBS 10 days after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34272622/
GBS 11 days after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34187803/
GBS following AstraZeneca with papilledema as atypical onset: https://pubmed.ncbi.nlm.nih.gov/34418708/
GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34330729/
GBS in a 63yo patient who had previous vaccine associated GBS syndrome following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34810163/
Recurrence of GBS following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34468703/
3 cases of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34548920/
3 cases of GBS and 1 case of CIDP following AstraZeneca in Tasmania: https://pubmed.ncbi.nlm.nih.gov/34560365/
4 cases of GBS following Astra Zeneca
7 cases of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34114256/
19 cases of GBS following J&J, Pfizer, and Astra Zeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34644738/
GBS following vaccination, a review of 39 cases: https://pubmed.ncbi.nlm.nih.gov/34648420/
2 cases of Sensory GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416410/
**Bilateral facial weakness with paresthesia variant of GBS following AstraZeneca:** [https://pubmed.ncbi.nlm.nih.gov/34261746/](https://pubmed.ncbi.nlm.nih.gov/34261746/)


**GBS presenting as bifacial diplegia in 2 patients following AstraZeneca:** [https://pubmed.ncbi.nlm.nih.gov/34649856/](https://pubmed.ncbi.nlm.nih.gov/34649856/)

---

**Miller Fisher Syndrome:**


**Miller Fisher syndrome after 2nd dose of Pfizer vaccination in a patient with resolved covid-19**

---

**Encephalopathy:**

**Facial Weakness, extremity weakness, encephalopathy, and severe refractory ITP following Moderna:** [https://pubmed.ncbi.nlm.nih.gov/33854395/](https://pubmed.ncbi.nlm.nih.gov/33854395/)

---

**CIDP:**


---

**Akathisia:**

**Transient akathisia after Pfizer**

---

**Phantosmia:**


---

**Bells Palsy / Nerve Palsy:**


**34yoF with Bells Palsy 2 days after Moderna:** [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143982/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143982/)

**36yo with Bells Palsy, left arm tingling/numbness/weakness following mRNA vaccination:** [https://pubmed.ncbi.nlm.nih.gov/34336436/](https://pubmed.ncbi.nlm.nih.gov/34336436/)


**57yoF with Bells Palsy <36 hours after 2nd dose of Pfizer:** [https://pubmed.ncbi.nlm.nih.gov/33594349/](https://pubmed.ncbi.nlm.nih.gov/33594349/)

**61yoM with Bells Palsy after each dose of Pfizer:** [https://pubmed.ncbi.nlm.nih.gov/34281950/](https://pubmed.ncbi.nlm.nih.gov/34281950/)

**Bells Palsy following mRNA and inactivated (CoronaVac) vaccines: a case series and nested case-control study:** [https://pubmed.ncbi.nlm.nih.gov/34411532/](https://pubmed.ncbi.nlm.nih.gov/34411532/)

**Rate of Bells Palsy following mRNA vaccination is 2-3x higher than expected:** [https://pubmed.ncbi.nlm.nih.gov/34111409/](https://pubmed.ncbi.nlm.nih.gov/34111409/)

---

**NMOSD:**


Optic neuritis and transverse myelitis in MS patient after Astrazeneca vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205198/

Multiple Sclerosis:
Patient's first MS Flare following Pfizer
New onset MS in a 32yoF patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34804388/
New onset of MS in a 40yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34700047/
3 new cases of MS, 13 flares of MS after Pfizer, Moderna, and Astra Zeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34480607/
4 cases of activation of stable MS, 2 cases of new MS, 1 case of new onset neuromyelitis optica after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34447349/
5 cases of new diagnosis of multiple sclerosis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34922126/

Optic neuritis and transverse myelitis in MS patient after Astrazeneca vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205198/

Myasthenia Gravis:
New onset Myasthenia Gravis in 82yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709075/

Cerebral Venous Thrombosis:
CVA and Thrombocytopenia following Astrazeneca: https://pubmed.ncbi.nlm.nih.gov/34175640/
Cerebral venous thrombosis in a 61yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34796065/
Cerebral venous sinus thrombosis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34783932/
Central venous sinus thrombosis with subarachnoid hemorrhage in a 45yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34478433/
Cerebral venous thrombosis and pulmonary embolus following AstraZeneca: https://www.sciencedirect.com/.../pii/S0196064421003425
Cerebral venous sinus thrombosis, subarachnoid hemorrhage, and thrombocytopenia following Astrazeneca: https://pubmed.ncbi.nlm.nih.gov/34485807/
Cerebral Venin sinus thrombosis, review of European cases: https://pubmed.ncbi.nlm.nih.gov/34293217/
Review of European data of Cerebral venous thrombosis with cytopenia, observed in Pfizer, Moderna, and AstraZeneca https://pubmed.ncbi.nlm.nih.gov/34375510/
### Intracerebral Hemorrhage / Strokes / etc:


### Aphasia:


### Neuro-Oncologic:


### Headache / Aseptic Meningitis:

- Steroid responsive aseptic meningitis after Pfizer in a 62yF: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566612/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566612/)

### Encephalitis / Delirium:

- Acute disseminated encephalitis following Pfizer: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294707/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294707/)
Acute Disseminated Encephalitis in a young female following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34480527/
Acute encephalitis, myoclonus, and sweet syndrome after mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34312136/
Acute psychosis due to anti-NMDA encephalitis in a young female in her 20s following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34803896/

Other:
Severe dyskinesia in Parkinson Patient following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34368991/
Hemichorea following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34811599/
3 cases of worsening complex regional pain syndrome following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34809486/
Cytotoxic lesion of the Corpus Callousum following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34402238/
Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34432055/
Three cases: CVA, left facial nerve palsy, and myelitis all following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34507266/

Pulmonary
Delayed hypersensitivity to Pfizer presenting with pneumonitis and rash: https://pubmed.ncbi.nlm.nih.gov/34813953/
2 cases of eosinophilic pneumonia following vaccination: https://pubmed.ncbi.nlm.nih.gov/34803208/
Interstitial lung disease after COVID-19 vaccination may be more common in Asians: https://pubmed.ncbi.nlm.nih.gov/34850213/
Acute eosinophilic pneumonia in a 37yo M following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34803207/
Pulmonary Embolus following Moderna: https://pubmed.ncbi.nlm.nih.gov/34452028/
2 cases of Pulmonary embolus following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34804412/

Cardiac:

General:
American Heart Association: Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults
American Heart Association: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines
Note the distinction between myocarditis, novel coronavirus myocarditis, and covid-19 vaccine associated myocarditis: https://pubmed.ncbi.nlm.nih.gov/34791441/
JAMA article, concerns for perimyocarditis underreporting, review of 40 hospitals: [https://jamanetwork.com/journals/jama/fullarticle/2782900](https://jamanetwork.com/journals/jama/fullarticle/2782900)


mRNA and Pericarditis/myocarditis risk compared to other vaccine types: [https://pubmed.ncbi.nlm.nih.gov/34834458/](https://pubmed.ncbi.nlm.nih.gov/34834458/)

ACS risk factor biomarkers increase after mRNA vaccination: [https://www.thecardiologyadvisor.com/home/topics/acs/acute-coronary-syndrome-acs-biomarkers-mrna-covid19-vaccine/?s=09&fbclid=IwAR2SRmzW0Aj1dE5MwiJTTcZHAHbR1ldl6C2Hpztm8Co_46AV5qss-4-3NV8](https://www.thecardiologyadvisor.com/home/topics/acs/acute-coronary-syndrome-acs-biomarkers-mrna-covid19-vaccine/?s=09&fbclid=IwAR2SRmzW0Aj1dE5MwiJTTcZHAHbR1ldl6C2Hpztm8Co_46AV5qss-4-3NV8)


**Myocarditis - Pericarditis - Reports:**


Recurrence of myocarditis after vaccination


Myocarditis in a 15yo following Pfizer: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369878/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369878/)

Myopericarditis in a 16yo following vaccination


| Myocarditis in a 18yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34804729/ |
| Myocarditis in a middle aged male with significant left ventricular dysfunction following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34795198/ |
| 70yoF with myocarditis following J&J Vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270733/ |
| Biopsy proven lymphocytic myocarditis following 1st mRNA vaccination in a 40yo: https://pubmed.ncbi.nlm.nih.gov/34487236/ |
| Cardiomyopathy of acute myocarditis following mRNA in a 24yoM: https://pubmed.ncbi.nlm.nih.gov/34402228/ |
| Cardiac MRI findings in young adults following mRNA vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34496880/ |
| Myopericarditis following mRNA vaccination: the role of cardiac biomarkers and multimodality imaging: https://pubmed.ncbi.nlm.nih.gov/34487161/ |
| Myocarditis should be consider in those with a troponin rise and unobstructed arteries following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34463755/ |
| Myocarditis Associated with COVID-19 vaccination: echocardiography, cardiac tomography, and magnetic resonance imaging findings: https://pubmed.ncbi.nlm.nih.gov/34428917/ |
| Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA vaccine immunization: https://pubmed.ncbi.nlm.nih.gov/34787887/ |
| Fulminant myocarditis and systemic hyperinflammation in 2 patients following mRNA: https://pubmed.ncbi.nlm.nih.gov/34416319/ |
| 2 cases of histological confirmed myocarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34407340/ |
| Two cases of myocarditis |
| 3 cases of cardiac manifestation following Pfizer: https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab177/6311674 |
| 4 cases of Myocarditis and their Cardiac MRI findings: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245050/ |
| 4 cases of myocarditis: https://pubmed.ncbi.nlm.nih.gov/34396358/ |
| 6 cases of men age 17-37 with myocarditis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219373/ |
| 8 cases of myocarditis in adolescents following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34319393/ |
| 13 cases of Myocarditis in adolescents following Pfizer: https://www.jpeds.com/article/S0022-3476(21)00665-X/fulltext |
| Review of 15 published cases of myocarditis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272967/ |
| Myocarditis and pericarditis due to mRNA vaccines in 19 cases: https://pubmed.ncbi.nlm.nih.gov/34805376/ |
| Myocarditis in 23 military members: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601 |
| Review of 29 published cases of acute myopericarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34356586/ |
| Review of 214 myocarditis cases:: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233865/ |

<p>| Cardiomyopathy: |</p>
<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute MI:</strong></td>
<td>3 cases of acute infarct-like myocarditis (2 Pfizer, 1 AstraZeneca):</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325525/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325525/</a></td>
</tr>
<tr>
<td><strong>Hypertension:</strong></td>
<td>Hypertension following mRNA vaccination:</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206586/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206586/</a></td>
</tr>
<tr>
<td></td>
<td>Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine</td>
<td></td>
</tr>
<tr>
<td><strong>Tachycardia:</strong></td>
<td>Isolated tachycardia in a 29yoF following Pfizer:</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34466331/">https://pubmed.ncbi.nlm.nih.gov/34466331/</a></td>
</tr>
<tr>
<td></td>
<td>Two cases of vaccine induced cardiac conduction disturbance following Pfizer and AstraZeneca:</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34796078/">https://pubmed.ncbi.nlm.nih.gov/34796078/</a></td>
</tr>
<tr>
<td><strong>Other:</strong></td>
<td>Posttransplant lymphoproliferative disorder after AstraZeneca in a heart transplant recipient:</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34702598/">https://pubmed.ncbi.nlm.nih.gov/34702598/</a></td>
</tr>
<tr>
<td><strong>GI:</strong></td>
<td>Risk of adverse events and reported relapse after COVID-19 vaccination in patients with IBD:</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34819330/">https://pubmed.ncbi.nlm.nih.gov/34819330/</a></td>
</tr>
<tr>
<td><strong>Gastroparesis:</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Pancreas:

### Hepatitis:
- **41yo F with Autoimmune hepatitis following Moderna**: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197609/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197609/)
- **71yoF with Autoimmune hepatitis after mRNA vaccine (Moderna)**
- **80yoF with autoimmune hepatitis following Pfizer**: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186938/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186938/)
- **35yoF with autoimmune hepatitis following Pfizer**: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/)
- **New Onset autoimmune hepatitis following mRNA vaccination in a 36yoF with Primary sclerosing cholangitis**: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384483/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384483/)
- **56yoF with autoimmune hepatitis following Moderna**: [https://www.journal-of-hepatology.eu/article/S0168-8278(21)00424-4/fulltext](https://www.journal-of-hepatology.eu/article/S0168-8278(21)00424-4/fulltext)
- **Liver injury in a liver transplant patient following mRNA vaccination**: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214934/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214934/)
- **16 cases of liver injury following Pfizer and Moderna: a multicenter case series**: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324396/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324396/)
- **Reactivation of Hepatitis C infection following Pfizer in a 82yoF**: [https://www.dovepress.com/hepatitis-c-virus-reactivation-following-covid-19-vaccination--a-case--peer-reviewed-fulltext-article-IMCRJ?fbclid=IwAR3u0x1baFcAZz1eOrNsXsgmrflUYt0EJV2SmoXA75RiplFQbPrtSAlo2GAs](https://www.dovepress.com/hepatitis-c-virus-reactivation-following-covid-19-vaccination--a-case--peer-reviewed-fulltext-article-IMCRJ?fbclid=IwAR3u0x1baFcAZz1eOrNsXsgmrflUYt0EJV2SmoXA75RiplFQbPrtSAlo2GAs)

### Other:
- **Inflammatory Bowel Disease triggered by Pfizer vaccination**: [https://pubmed.ncbi.nlm.nih.gov/34922342/](https://pubmed.ncbi.nlm.nih.gov/34922342/)
3 cases of portal vein thrombosis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34776709/

Renal:

**ANCA:**
- ANCA glomerulonephritis after Moderna: https://www.kidney-international.org/article/S0085-2538(21)00555-X/fulltext

**Nephrotic Syndrome:**
- Nephrotic Syndrome following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257404/

**Minimal Change Disease:**
- MCD relapse following Pfizer in a man in his mid-60s: https://pubmed.ncbi.nlm.nih.gov/34023417/
- MCD relapse following Pfizer in a 34yoF: https://pubmed.ncbi.nlm.nih.gov/33964312/
- Severe Minimal change disease relapse 3 days following Pfizer: https://europepmc.org/article/PMC8156905
- Minimal Change Disease with nephrotic syndrome and AKI following Pfizer in a 50yoM: https://pubmed.ncbi.nlm.nih.gov/33839200/
- Minimal change disease in 80's yoM following first dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/33992727/
- Minimal change disease and AKI in a 77yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34000278/
- Minimal change disease 4 days after Pfizer in a 45yoF: https://pubmed.ncbi.nlm.nih.gov/34721864/
- Relapse of minimal change disease with severe nephrotic syndrome in a 22yoM following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156905/
<table>
<thead>
<tr>
<th>Condition</th>
<th>Details</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimal Change disease</td>
<td>and Severe AKI following AstraZeneca</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34242687/">https://pubmed.ncbi.nlm.nih.gov/34242687/</a></td>
</tr>
<tr>
<td>2 cases of minimal change disease following</td>
<td>vaccination</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34779088/">https://pubmed.ncbi.nlm.nih.gov/34779088/</a></td>
</tr>
<tr>
<td>3 cases of minimal change disease following</td>
<td>2nd dose of mRNA vaccine</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34337193/">https://pubmed.ncbi.nlm.nih.gov/34337193/</a></td>
</tr>
<tr>
<td>13 cases of new or relapsing minima change</td>
<td>disease following mRNA vaccination</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34632166/">https://pubmed.ncbi.nlm.nih.gov/34632166/</a></td>
</tr>
<tr>
<td>Nephropathy / IGA Vasculitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgA nephropathy presenting as rapidly</td>
<td>progressive glomerulonephritis in a 13yo following 1st dose of Pfizer</td>
<td></td>
</tr>
<tr>
<td>IgA and crescentic glomerulonephritis</td>
<td>following Pfizer</td>
<td></td>
</tr>
<tr>
<td>IgA nephropathy flare up following Moderna</td>
<td></td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079938/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079938/</a></td>
</tr>
<tr>
<td>IgA nephropathy after mRNA vaccine</td>
<td></td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34278290/">https://pubmed.ncbi.nlm.nih.gov/34278290/</a></td>
</tr>
<tr>
<td>IgA nephropathy flare-up following vaccination</td>
<td></td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34415336/">https://pubmed.ncbi.nlm.nih.gov/34415336/</a></td>
</tr>
<tr>
<td>IgA nephropathy in 2 patients after Pfizer</td>
<td></td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256683/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256683/</a></td>
</tr>
<tr>
<td>3 cases of IgA nephropathy patients developing</td>
<td>exacerbations following mRNA vaccine</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166778/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166778/</a></td>
</tr>
<tr>
<td>2 cases of IgA nephropathy patients developing</td>
<td>exacerbations following Moderna</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256683/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256683/</a></td>
</tr>
<tr>
<td>2 cases of IgA Nephropathy patients developing</td>
<td>hematuria after Pfizer</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329426/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329426/</a></td>
</tr>
<tr>
<td>Reactivation of IgA vasculitis following</td>
<td>Moderna</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260100/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260100/</a></td>
</tr>
<tr>
<td>Reactivation of IgA vasculitis following</td>
<td>Pfizer</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34848431/">https://pubmed.ncbi.nlm.nih.gov/34848431/</a></td>
</tr>
<tr>
<td>Case of IgA vasculitis following Pfizer</td>
<td></td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34535924/">https://pubmed.ncbi.nlm.nih.gov/34535924/</a></td>
</tr>
<tr>
<td>IgA vasculitis following AstraZeneca</td>
<td></td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34509658/">https://pubmed.ncbi.nlm.nih.gov/34509658/</a></td>
</tr>
<tr>
<td>IgA vasculitis with renal and skin involvement</td>
<td>following vaccination</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34779011/">https://pubmed.ncbi.nlm.nih.gov/34779011/</a></td>
</tr>
<tr>
<td>Membranous nephropathy following mRNA vaccine</td>
<td></td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34419553/">https://pubmed.ncbi.nlm.nih.gov/34419553/</a></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Glomerulopathies after vaccination against covid-19: four cases with three different vaccines in Argentina: https://pubmed.ncbi.nlm.nih.gov/34728874/ 

Rheumatology/Endocrinology/Orthopedics

General:

Hyper-inflammation after COVID-19 mRNA vaccination: at the cross roads of multi-inflammatory disease and adult onset still's disease


11% of patients with rheumatic and MSK diseases report disease flare following 2 dose mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34346185/

Macrophage Activation Syndrome:


Still's Disease:


Adult onset Still's disease in a 36yo following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34962116/


Lupus:


Lupus exacerbation following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/

27 cases of lupus flare following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34782941/


Emergence of new onset SLE following vaccination: https://pubmed.ncbi.nlm.nih.gov/34450645/

Hyperglycemic / Glucose:


3 cases of exacerbation of hyperglycemia in patients with type 2 diabetes following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143905/
3 cases of hyperglycemic emergencies following Pfizer and Moderna: https://pubmed.ncbi.nlm.nih.gov/34604689/
Perturbation of blood glucose following vaccination, a review of 20 adults: https://pubmed.ncbi.nlm.nih.gov/34375490/

Thyroid:
Silent thyroiditis following Pfizer, subacute thyroiditis following moderna, and Graves disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34792795/
Subacute Thyroiditis: https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1947102?fbclid=IwAR02FYW94iQGbu6e2uTpD42Xolwp6QHzwhDBWotULT4ZCGR5sVKkyexbRg
Subacute thyroiditis following vaccination: https://pubmed.ncbi.nlm.nih.gov/34690055/
Subacute thyroiditis following Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34777881/
42yoF with subacute thyroiditis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34907904/
Two cases of subacute thyroiditis after Moderna and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34504856/
4 cases of subacute thyroiditis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34893014/
Two cases of thyroiditis after Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34693241/
Two cases of Graves disease following vaccination: https://pubmed.ncbi.nlm.nih.gov/33858208/
Two more cases of Graves disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34342859/
Hyperthyroidism following vaccination: https://pubmed.ncbi.nlm.nih.gov/34696214/

Adrenal:
5 cases of adrenal crisis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34358373/
Myositis in a 56yoF following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/33647971/
2 cases of Löfgren's syndrome following AstraZeneca and Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34835244/
mRNA induced rhabdomyolysis and fasciitis: https://pubmed.ncbi.nlm.nih.gov/34435250/

Inflammation / Arthritis:
Quadrilateral space region inflammation and other incidental findings on shoulder MRI following Pfizer COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34306275/


**Vasculitis and bursitis on 18F FDG-PET/CT following mRNA vaccination:** [https://pubmed.ncbi.nlm.nih.gov/34495381/](https://pubmed.ncbi.nlm.nih.gov/34495381/)

**Remitting seronegative symmetrical synovitis with pitting edema following Pfizer:** [https://pubmed.ncbi.nlm.nih.gov/34348912/](https://pubmed.ncbi.nlm.nih.gov/34348912/)

**COVID-19 vaccination and large0vessel giant cell arteritis:** [https://pubmed.ncbi.nlm.nih.gov/34788208/](https://pubmed.ncbi.nlm.nih.gov/34788208/)

**HSP:**


**Psoriasis:**


**Cryoglobulinaemia:**

**Treatment Guide to Thrombotic Thrombocytopenia Following Vaccination:** [https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia)


Coagulopathies after vaccination against SARS-COV-2 may be derived from a combo of spike protein and adenovirus vector-triggered signaling pathways: https://arxiv.org/abs/2109.00089?fbclid=IwAR2orycgbxqSNXL9A4XjNwEAZBumiRbRKsfW8KL5qiJUXSWwgmLiMtc4Z4


Safety warning for AstraZeneca in patients with sickle cell disease: https://mjhid.org/index.php/mjhid/article/view/4708?fbclid=IwAR2kMtsqqwiYxxQ9xIxvDFdOST-yTPqjAro-fgaEp460JeHd0QwBxx4DPg

**Hemolysis**


Autoimmune hemolytic anemia: https://pubmed.ncbi.nlm.nih.gov/34150386/

Autoimmune hemolytic anemia following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34258873/


Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor following Moderna: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26262


**Anemia**


**ITP**

ITP and AIHA following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274740/

ITP Exacerbation in previous stable patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34307734/


ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34155844/

ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34382388/

ITP following booster dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34820240/

Secondary ITP and resulting hemorrhage and hematoma after minor oral surgery after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34314875/

ITP and diffuse papular rash following Moderna: https://www.scienceopen.com/document_file/691feaa0-8e64-40c4-9553-40382bd5ac48/PubMedCentral/691feaa0-8e64-40c4-9553-40382bd5ac48.pdf


ITP in 1st trimester of pregnancy 13 days following vaccination in the US: https://pubmed.ncbi.nlm.nih.gov/34420249/

20yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34381692/

22yoM with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33476455/
24yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34754937/
26yoF with ITP and acute liver injury following Moderna: https://pubmed.ncbi.nlm.nih.gov/34330722/
28yoM with ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/33934330/
37yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34732627/
39yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34285180/
41yoF with secondary ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34059544/
41yoM with ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34377889/
54yoF with ITP following Pfizer: https://www.cureus.com/articles/56899-newly-diagnosed-idiopathic-thrombocytopenia-post-covid-19-vaccine-administration
63yoF with ITP following Johnson and Johnson: https://pubmed.ncbi.nlm.nih.gov/34469919/
67yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34513446/
68yoF with ITP in Korea following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34751013/
68yoF with ITP following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385179/
69yoF with refractory ITP following Pfizer: https://journals.lww.com/americantherapeutics/Citation/2021/08000/Immune_Thrombocytopenic_Purpura_Associated_With.24.aspx
74yoM with ITP following Moderna: https://www.dovepress.com/severe-refractory-immune-thrombocytopenia-occurring-after-sars-cov-2-v-peer-reviewed-fulltext-article-JBM
84yoM with ITP following Pfizer: https://link.springer.com/article/10.1007/s11739-021-02778-w
86yoM with ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34446449/
2 cases of ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34114220/
3 cases of ITP following Pfizer and AstraZeneca: https://www.mjhid.org/index.php/mjhid/article/view/4669/4043
3 cases reports of ITP following Pfizer and J&J: https://ehoonline.biomedcentral.com/articles/10.1186/s40164-021-00235-0
3 cases: recurrent AvWD and acquired hemophilia A after Moderna, PNH flare following Moderna, and ITP flare following Moderna: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic
3 cases of ITP, 2 in chronic individuals and 1 in a healthy individual, following Pfizer and Moderna: https://pubmed.ncbi.nlm.nih.gov/34716890/
3 cases of ITP in elderly patients following vaccination: https://www.hindawi.com/journals/crihem/2016/7913092/
4 cases of severe ITP following Pfizer, Moderna, and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34653943/
20 cases of ITP following Pfizer and Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/
21 cases of ITP following Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34756770/
36 Cases of ITP following Pfizer and Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011062/
77 denovo cases of ITP and 19 ITP exacerbation following vaccination: https://pubmed.ncbi.nlm.nih.gov/34587251/
12% of chronic ITP patients have exacerbation of ITP in 2-5 days following vaccination: https://pubmed.ncbi.nlm.nih.gov/34075578/
Thrombolytic / Thrombocytopenia


Superior ophthalmic Vein Thrombosis and Thrombocytopenia following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265377/

DVT and PE and positive HIT panel following mRNA Vaccine: https://pubmed.ncbi.nlm.nih.gov/34117206/

An unusual presentation of acute DVT after moderna vaccine: https://pubmed.ncbi.nlm.nih.gov/34790811/

3 patients with venous thromboembolism following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/

Thrombosis with Thrombocytopenia following Moderna: https://www.acpjournals.org/doi/full/10.7326/L21-0244

34yoF with vaccine induced thrombotic thrombocytopenia following Moderna: https://pubmed.ncbi.nlm.nih.gov/34804389/


Case study of Thrombosis and Thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34781321/

Eltromopag for refractory vaccine-induced immune thrombotic thrombocytopenia in a 64yoF following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34797474/

TTP Following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34264514/

Acquired TTP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34309715/


Flare of compensated congenital TTP following vaccination: https://pubmed.ncbi.nlm.nih.gov/34693915/

Thrombocytopenia in a teen with sickle cell disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34331506/

5 cases of prothrombotic immune thrombocytopenia after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34323939/

20 cases of Thrombocytopenia following Pfizer and Moderna: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26132

Review of 50 cases of thrombocytopenia following Astrazeneca, Pfizer, Moderna: https://pubmed.ncbi.nlm.nih.gov/34332437/

68yoF with extensive thrombosis after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34400433/


Fatal ICH due to Thrombotic Thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34402235/

Five cases with a combination of cerebral venous thrombosis, intracerebral hemorrhage and thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34393988/

VITT

Confusion and abdominal pain due to VITT following vaccination: https://pubmed.ncbi.nlm.nih.gov/34346657/

**Malignant CVA due to VITT following AstraZeneca:** [https://pubmed.ncbi.nlm.nih.gov/34341358/](https://pubmed.ncbi.nlm.nih.gov/34341358/)


**Other:**


- **Skin, nose, and gingival bleeding episodes after AstraZeneca:** [a large population-based cohort study](https://pubmed.ncbi.nlm.nih.gov/34479760/)

- **Haemophagocytosis and atypical lymphocytes on bone marrow biopsy following vaccination:** [https://pubmed.ncbi.nlm.nih.gov/34312842/](https://pubmed.ncbi.nlm.nih.gov/34312842/)

- **3 cases of HLH following AstraZeneca:** [https://jcp.bmj.com/content/early/2021/07/22/jclinpath-2021-207760](https://jcp.bmj.com/content/early/2021/07/22/jclinpath-2021-207760)


**Oncology**

**General**


- **Coordination and optimization of FDG PET/CT and vaccination; lessons learned in the early stages of mass vaccination:** [https://pubmed.ncbi.nlm.nih.gov/34029956/](https://pubmed.ncbi.nlm.nih.gov/34029956/)


- **Hypermetabolic lymphadenopathy following Pfizer, incidence assessed by FDG PET-CT and relevance to study interpretation, a review of 728 vaccinated patients:** [https://pubmed.ncbi.nlm.nih.gov/33774684/](https://pubmed.ncbi.nlm.nih.gov/33774684/)

**Lymphadenopathy / Adenopathy:**


- **Axillary lymphadenopathy following mRNA vaccination**

- **Ipsilateral axillary adenopathy following mRNA vaccination:** [https://pubmed.ncbi.nlm.nih.gov/34333959/](https://pubmed.ncbi.nlm.nih.gov/34333959/)


False positive axillary lymph nodes on FDG PET/CT resulting from covid-19 immunization: https://pubmed.ncbi.nlm.nih.gov/33883486/

4 cases of axillary adenopathy following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34303188/


163 cases of axillary adenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34257025/

mRNA vaccination: age and immune status and its association with axillary lymph node PET/CT uptake, a review of 426 patients: https://pubmed.ncbi.nlm.nih.gov/33893188/

Ipsilateral avid axillary lymph node update at FDG PET/CT persists in 29% of patients 7-10 weeks after 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/33904778/


Axillary lymphadenopathy at the time of vaccination: ten recommendations from the European society of breast imaging: https://pubmed.ncbi.nlm.nih.gov/34417642/

Evolving bilateral hypermetabolic axillary lymphadenopathy on FDG PET/CT following 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/

Axillary lymph nodes hypermetabolism after Pfizer in cancer patients undergoing 18F-FDG PET/CT: a cohort study: https://pubmed.ncbi.nlm.nih.gov/33782299/

Reactive axillary lymphadenopathy to covid-19 vaccination on F-FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33820864/


Supraclavicular lymphadenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34414929/

Rare case of contralateral supraclavicular lymphadenopathy after vaccination: CT and ultrasound findings: https://pubmed.ncbi.nlm.nih.gov/34667486/


Cervical lymphadenopathy following Pfizer

13 cases of Cervical lymphadenopathy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241354/

50yoM with adenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34406229/

Review of 24 cases of lymphadenopathy and their ultrasound findings in the US: https://pubmed.ncbi.nlm.nih.gov/34356507/


2 cases of Kikuchi-Fujimoto Disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34835182/

Mammographic and sonographic findings in the breast and axillary tail following vaccination: https://pubmed.ncbi.nlm.nih.gov/34340203/


COVID-19 vaccine related axillary and cervical lymphadenopathy in patients with current or prior breast cancer and other malignancies: cross sectional imaging findings on MRI, CT, and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
The challenge of staging breast cancer with PET/CT in the era of covid vaccination:https://pubmed.ncbi.nlm.nih.gov/33795590/
DOTATATE-avid bilateral axillary and subpectoral lymphadenopathy induced from mRNA vaccination visualized on PET/CT: https://pubmed.ncbi.nlm.nih.gov/33795589/
DOTATOC-avid lymphadenopathies induced by mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34363083/
3 cases of supraclavicular and axillary lymphadenopathy induced by vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT: https://pubmed.ncbi.nlm.nih.gov/34507331/
Moderna vaccination mimicking lymph-node progression in a patient with melanoma: https://pubmed.ncbi.nlm.nih.gov/34433198/
COVID-19 vaccine as cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma: https://pubmed.ncbi.nlm.nih.gov/33675368/
Pfizer vaccination manifesting as incidental lymph node uptake on 18F-FDG PET/CT in a melanoma patient: https://pubmed.ncbi.nlm.nih.gov/33661193/
Axillary adenopathy following AstraZeneca resulting in possible misinterpretation of PET scan in metastatic melanoma patient: https://pubmed.ncbi.nlm.nih.gov/34414110/
8 patients where mRNA vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: https://pubmed.ncbi.nlm.nih.gov/34280870/
False Positive FDG PET CT after vaccination in a woman treated for metastatic breast cancer: https://pubmed.ncbi.nlm.nih.gov/34308402/
mRNA vaccination induced lymphadenopathy mimics lymphoma progression on FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33591026/
Avid left axillary nodes and intense diffuse splenic uptake and moderate diffuse bone marrow uptake on PET 1 week after vaccination: https://pubmed.ncbi.nlm.nih.gov/34269722/

FDG-PET / PET-CT findings:
Vaccination effect on tracer uptake with FDG-PET/CT: https://pubmed.ncbi.nlm.nih.gov/34297113/
COVID-19 vaccination induced axillary nodal update on 18F FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33638003/
Prevalence and significance of hypermetabolic lymph nodes detected by 18F FDG PET/CT after vaccination: a systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34451859/
AstraZeneca vaccination included lymphadenopathy on 18F choline PET/CT-not only an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
Abnormal PET following vaccination: https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.29262
Positive PET following vaccination: https://pubmed.ncbi.nlm.nih.gov/34301777/
Vaccine related lymph node activation-patterns of uptake on PET-CT: https://pubmed.ncbi.nlm.nih.gov/34131510/
The day after mass COVID vaccination: higher hypermetabolic lymphadenopathy detection on PET/CT and impact on oncologic management: https://pubmed.ncbi.nlm.nih.gov/34503150/
Frequency and characteristics of nodal and deltoid FDG and C-Choline update on PET performed after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34009000/
Adverse reactions following vaccination in patients with cancer undergoing treatment: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527840/
Radiation recall pneumonitis on FDG/ PET/CT triggered by mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34739397/

**Lymphoma**

**Other:**
Thymic hyperplasia after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34462647/

**Dermatology/Plastics:**
60yo with Steven Johnson Syndrome: https://pubmed.ncbi.nlm.nih.gov/34081806/
Steven Johnson Syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34384729/

Pemphigus Vulgaris

An unusual presentation of pemphigus foliaceus following vaccination: https://pubmed.ncbi.nlm.nih.gov/34817063/

Morpilliform Rash

A case of erythroderma with elevated serum immunoglobulin E and thymus and activation-regulated chemokine levels following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34821411/

Spontaneous urticaria after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34692313/


40yoM with Pityriasis rosea after Moderna: https://pubmed.ncbi.nlm.nih.gov/34110010/


1 case of Pityriasis rosea and 3 cases of urticaria following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34478204/

2 cases of Pityriasis rosea-like eruptions following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33982814/

Pityriasis rosea following Moderna vaccination, a case series: https://pubmed.ncbi.nlm.nih.gov/34816549/


Two cases of papulo-pustular rosacea-like eruptions following Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416044/


Pityriasis Rubra Pilaris like eruption following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34379821/

Lymphomatoid drug reaction developed after Pfizer vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption: https://pubmed.ncbi.nlm.nih.gov/34751995/


3 cases of new onset acral hand lesions following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34310777/

2 patients with eczematous cutaneous reactions following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236729/

Case study of 19 patients with cutaneous adverse reactions following vaccination: https://pubmed.ncbi.nlm.nih.gov/34698094/

New onset synovitis and palmoplantar psoriasis flare up after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236728/


Purpura annularis telangiectodes following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236717/
Flagellate Purpura following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416052/
Pigmented purpuric dermatosis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34791786/
Symmetrical drug related intertriginous and flexural exanthema like eruption following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34399001/
Vitiligo following Pfizer: https://onlinelibrary.wiley.com/doi/10.1111/ced.14842
Vitiligo in a Ulcerative Colitis Patient following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34498300/
Bacillus Calmette-Guerin scar flare after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34344774/
Palms and Soles Itchiness following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34391695/
Resistant pruritis skin rash following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34358176/
Necrotic eschars at injection sites one week after 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34337117/
Acute generalized exanthematous pustulosis induced by Moderna: https://pubmed.ncbi.nlm.nih.gov/34466640/
Delayed local skin reactions: https://www.nejm.org/doi/full/10.1056/NEJMc2102131?fbclid=IwAR0P6wjXI04swT4wz0EJCb7v14e2Si-O9AbOuhlVisVHFhckGEv7pyj0
Delayed skin reactions following mRNA vaccine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288253/
11 patients with delayed skin reaction after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34433495/
Additional 12 Patients with Delayed Local Reactions: https://www.nejm.org/doi/full/10.1056/NEJMc2102131
138 Delayed Hypersensitivity Reactions Following vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294276/
Delayed cutaneous hypersensitivity reaction following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34351606/
Cutaneous skin manifestation following Moderna with Hypersensitivity reaction Histopathology: https://pubmed.ncbi.nlm.nih.gov/34414254/
2 cases of delayed local reactions following Moderna:https://journals.lww.com/infectdis/Fulltext/2021/07000/Delayed_Skin_Rash_After_Receiving_SARS_CoV_2_mRNA.19.aspx
4 cases of cutaneous hypersensitivity reactions following Moderna: https://pubmed.ncbi.nlm.nih.gov/34485656/
5 Japanese cases of delayed large local reactions to Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34459023/
13 cases delayed local reactions following mRNA vaccine: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab518/6291929
COVID arm following Moderna detected by MR neurography: https://pubmed.ncbi.nlm.nih.gov/34746453/
Covid vaccine arm may present after both mRNA vaccines vaccination: https://pubmed.ncbi.nlm.nih.gov/34416053/
405 cases of dermatologic reactions following Pfizer, Moderna, and Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34254291/
Erythema Migrans like rash after Moderna: https://pubmed.ncbi.nlm.nih.gov/34250736/
Bullous eruption following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34416058/
Atypical erythema multiforme related to Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34473839/
Erythema multiforme after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34962029/
Soft Tissue Filler Inflammatory Reaction after vaccination
Immune Response to fillers and breast implants after vaccination: https://pubmed.ncbi.nlm.nih.gov/34174765/
COVID-toes after mRNA vaccination
Leukocytoclastic vasculitis flare following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33928638/
Leukocytoclastic vasculitis in a 42yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34196469/
Leukocytoclastic vasculitis after Pfizer vaccine booster: https://pubmed.ncbi.nlm.nih.gov/34720009/
Leukocytoclastic vasculitis in a 68yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34713472/
Leukocytoclastic vasculitis after exposure to AstraZeneca vaccine: https://pubmed.ncbi.nlm.nih.gov/34836739/
Urticarial Vasculitis following vaccination: https://journals.lww.com/amjdermatopathology/Citation/9000/Unique_Case_of_Urticarial_Skin_Eruptions_After.97698.aspx
Possible case of mRNA vaccine induced small vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/
Cutaneous lymphocytic vasculitis following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795/
Pfizer induced reactivation of varicella and resulting small vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34310759/
Immune complex vasculitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34530771/
De novo vasculitis after Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166777/
2 cases of skin color discoloration following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34310755/
A case series of rare cutaneous adverse events following vaccination: https://pubmed.ncbi.nlm.nih.gov/34363637/
Moderna Vaccine Induced Skin Rash: https://pubmed.ncbi.nlm.nih.gov/34423142/
Reactivation of BCH vaccination scars after vaccination with mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34930152/
Clinicopathological features of cutaneous reactions after mRNA vaccines, 11 cases: https://pubmed.ncbi.nlm.nih.gov/34459036/
3 cases of vesiculobullous non-IgE-mediated cutaneous reactions to Pfizer: https://pubmed.ncbi.nlm.nih.gov/34363258/
Sweet Syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34835143/
Clinical and histopathological spectrum of delayed adverse cutaneous reactions following covid-19 vaccination, a review of 12 cases: https://pubmed.ncbi.nlm.nih.gov/34292611/
Cutaneous reactions reported after Moderna and Pfizer vaccination: a registry based study of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
Response to McManon et al's... 414 cases: https://pubmed.ncbi.nlm.nih.gov/34801633/
Skin reactions to covid-19 vaccines: an AAD/ILDS registry update on reaction location and COVID vaccine type: https://pubmed.ncbi.nlm.nih.gov/34800601/
<table>
<thead>
<tr>
<th><strong>Ophthalmology:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General:</strong></td>
</tr>
<tr>
<td><strong>Macular Neuroretinopathy:</strong></td>
</tr>
<tr>
<td>Acute Macular Neuroretinopathy after AstraZeneca</td>
</tr>
<tr>
<td><strong>Corneal Graft Rejection:</strong></td>
</tr>
<tr>
<td>Full thickness corneal transplant rejection 3 days following Moderna: <a href="https://pubmed.ncbi.nlm.nih.gov/34690266/">https://pubmed.ncbi.nlm.nih.gov/34690266/</a></td>
</tr>
<tr>
<td>Bilateral Retinal Detachments 10 days after mRNA vaccination 22yoF: <a href="https://www.jem-journal.com/article/S0736-4679(21)00611-9/fulltext">https://www.jem-journal.com/article/S0736-4679(21)00611-9/fulltext</a></td>
</tr>
<tr>
<td><strong>Vein Occlusion / Retinal Necrosis</strong></td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>virus after Pfizer vaccination in 78yoM:</td>
</tr>
<tr>
<td>virus after Pfizer vaccination in 62yoM:</td>
</tr>
<tr>
<td>virus after Pfizer vaccination in 71yoM:</td>
</tr>
<tr>
<td>Oculomotor Palsy</td>
</tr>
<tr>
<td>21 cases of Uveitis following mRNA vaccination: <a href="https://pubmed.ncbi.nlm">https://pubmed.ncbi.nlm</a>.</td>
</tr>
<tr>
<td>nih.gov/34369440/</td>
</tr>
<tr>
<td>Optic Neuropathy</td>
</tr>
<tr>
<td>Relapse of stromal herpes keratitis following mRNA vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34823340/">https://pubmed.ncbi.nlm.nih.gov/34823340/</a></td>
</tr>
<tr>
<td>2 cases of Ipsilateral zoster ophthalmicus after Moderna and Johnson and</td>
</tr>
<tr>
<td>2 cases of herpes zoster ophthalmicus following vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34690265/">https://pubmed.ncbi.nlm.nih.gov/34690265/</a></td>
</tr>
<tr>
<td>Bilateral immune mediated keratolysis following AstraZeneca: <a href="https://pubmed.ncbi.nlm.nih.gov/34483273/">https://pubmed.ncbi.nlm.nih.gov/34483273/</a></td>
</tr>
<tr>
<td>Other:</td>
</tr>
<tr>
<td>34yoM with bilateral multifocal choroiditis following 2nd dose vaccination:</td>
</tr>
<tr>
<td>Acute painless bilateral blurring of vision following Pfizer due to Vogt-Koyanagi-Hara disease: https://</td>
</tr>
<tr>
<td>pubmed.ncbi.nlm.nih.gov/34505819/</td>
</tr>
<tr>
<td>Eyelid erythema after Pfizer vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a></td>
</tr>
<tr>
<td>34426009/</td>
</tr>
<tr>
<td>Transient eyelid edema following Pfizer: <a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a></td>
</tr>
<tr>
<td>34524252/</td>
</tr>
<tr>
<td>Disc edema in one eye and central serous chorioretinopathy in the other</td>
</tr>
<tr>
<td>following AstraZeneca: <a href="https://pubmed.ncbi.nlm.nih.gov/34783448/">https://pubmed.ncbi.nlm.nih.gov/34783448/</a></td>
</tr>
<tr>
<td>ENT</td>
</tr>
<tr>
<td>3 cases of Tinnitus following mRNA vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34120553/">https://pubmed.ncbi.nlm.nih.gov/34120553/</a></td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>18 cases of idiopathic sensorineural hearing loss, tinnitus, and/or vertigo following Moderna/Pfizer</td>
</tr>
<tr>
<td>ID</td>
</tr>
<tr>
<td>Herpes Zoster following Moderna</td>
</tr>
<tr>
<td>Herpes Zoster reactivation following Moderna</td>
</tr>
<tr>
<td>2 cases of herpes zoster following Pfizer</td>
</tr>
<tr>
<td>2 cases of herpes zoster in healthy young adults following vaccination</td>
</tr>
<tr>
<td>3 cases of Herpes Zoster following Vaccination (Moderna and AstraZeneca)</td>
</tr>
<tr>
<td>3 cases of Herpes Zoster after covid vaccination in patients with chronic urticaria being treated with cyclosporine</td>
</tr>
<tr>
<td>6 cases of Herpes Zoster following Pfizer</td>
</tr>
<tr>
<td>Varicella zoster reactivation and mRNA vaccines as a trigger</td>
</tr>
<tr>
<td>40 cases of HSV and VZV reactivation following mRNA vaccination</td>
</tr>
<tr>
<td>Autoantibody</td>
</tr>
<tr>
<td>A Possible Role for Anti-idiotypic Antibodies in SARS-CoV-2 Infection and Vaccination</td>
</tr>
<tr>
<td>MIS-V Multisystem Inflammatory Syndrome</td>
</tr>
<tr>
<td>3 cases of Multisystem Inflammatory Syndrome after Pfizer</td>
</tr>
<tr>
<td>Multisystem Inflammation in a 20yoM following Pfizer</td>
</tr>
<tr>
<td>MIS-A in a 21yoF following Moderna vaccination which was given 27 days after COVID infection</td>
</tr>
<tr>
<td>MIS-A in a 37yoF 10 days post 2nd Moderna COVID vaccine and 1 month from COVID infection: [<a href="https://pubmed.ncbi.nlm.nih.gov/34868588/">https://pubmed.ncbi.nlm.nih.gov/34868588/</a>]</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Multisystem inflammatory syndrome in children by covid-19 vaccination of adolescents in France: [<a href="https://pubmed.ncbi.nlm.nih.gov/34928295/">https://pubmed.ncbi.nlm.nih.gov/34928295/</a>]</td>
</tr>
<tr>
<td>Multisystem inflammatory syndrome in a COVID-19 vaccinated adolescent female with sickle cell disease: [<a href="https://pubmed.ncbi.nlm.nih.gov/34955521/">https://pubmed.ncbi.nlm.nih.gov/34955521/</a>]</td>
</tr>
<tr>
<td>Multisystem inflammatory syndrome following COVID-19 vaccination: ignored and underdiagnosed: [<a href="https://pubmed.ncbi.nlm.nih.gov/34940858/">https://pubmed.ncbi.nlm.nih.gov/34940858/</a>]</td>
</tr>
<tr>
<td>Postmortem investigation of fatalities following vaccination with COVID-19 vaccines: [<a href="https://pubmed.ncbi.nlm.nih.gov/34911186/">https://pubmed.ncbi.nlm.nih.gov/34911186/</a>]</td>
</tr>
<tr>
<td>Autopsy findings and causality relationship between death and covid-19 vaccination: a systematic review: [<a href="https://pubmed.ncbi.nlm.nih.gov/34945172/">https://pubmed.ncbi.nlm.nih.gov/34945172/</a>]</td>
</tr>
<tr>
<td>MIS-C in a male adolescent after his second dose of Pfizer: [<a href="https://pubmed.ncbi.nlm.nih.gov/34617315/">https://pubmed.ncbi.nlm.nih.gov/34617315/</a>]</td>
</tr>
<tr>
<td>Multisystem inflammatory syndrome in an adult following AstraZeneca: [<a href="https://pubmed.ncbi.nlm.nih.gov/34811978/">https://pubmed.ncbi.nlm.nih.gov/34811978/</a>]</td>
</tr>
<tr>
<td>Postvaccination MIS in an adult with no evidence of prior COVID-19 infection following AstraZeneca: [<a href="https://pubmed.ncbi.nlm.nih.gov/34852213/">https://pubmed.ncbi.nlm.nih.gov/34852213/</a>]</td>
</tr>
<tr>
<td>MIS-A in an adult woman 18 days following AstraZeneca vaccination: [<a href="https://pubmed.ncbi.nlm.nih.gov/34511054/">https://pubmed.ncbi.nlm.nih.gov/34511054/</a>]</td>
</tr>
<tr>
<td>Fatal Multisystem inflammatory syndrome after 2nd dose of Pfizer: [<a href="https://pubmed.ncbi.nlm.nih.gov/34586059/">https://pubmed.ncbi.nlm.nih.gov/34586059/</a>]</td>
</tr>
</tbody>
</table>

**Miscellaneous**

<table>
<thead>
<tr>
<th>SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538446/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538446/</a>]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases” [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/</a>]</td>
</tr>
<tr>
<td>The BNT162b2 mRNA vaccine against SARS-COV-2 reprograms both adaptive and innate immune response: [<a href="https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1?fbclid=IwAR1MV3eNa-8MZFJb_SZqAF0ycWrMM4uS_80cL2TA7_9C2MxyJkJdZnMjQ">https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1?fbclid=IwAR1MV3eNa-8MZFJb_SZqAF0ycWrMM4uS_80cL2TA7_9C2MxyJkJdZnMjQ</a>]</td>
</tr>
<tr>
<td>Does COVID-19 RNA based vaccines put at risk of immune-mediated diseases? [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/</a>]</td>
</tr>
<tr>
<td>International call for vaccine adverse reaction investigation: [<a href="https://www.researchgate.net/publication/351670290_SARS-CoV-2_mass_vaccination_Urgent_questions_on_vaccine_safety_that_demand_answers_from_international_health_agencies_regulatoryAuthorities_governments_and_vaccine_developers">https://www.researchgate.net/publication/351670290_SARS-CoV-2_mass_vaccination_Urgent_questions_on_vaccine_safety_that_demand_answers_from_international_health_agencies_regulatoryAuthorities_governments_and_vaccine_developers</a>?]</td>
</tr>
<tr>
<td>2_mass_vaccination_Urgent_questions_on_vaccine_safety_that_demand_answers_from_international_health_agencies_regulatoryAuthorities_governments_and_vaccine_developers?fbclid=IwAR1Gwfel6khY8ObziHNTG2riwS0Gezo0Cp8ziJaHlC91fceD2EkdMKmYw</td>
</tr>
<tr>
<td>Severe COVID-19 Vaccine (Pfizer) Side Effects are rare in older adults yet are linked with depressive symptoms</td>
</tr>
<tr>
<td>Serious adverse events following immunization with AstraZeneca in India, a single center experience: [<a href="https://pubmed.ncbi.nlm.nih.gov/34804334/">https://pubmed.ncbi.nlm.nih.gov/34804334/</a>]</td>
</tr>
<tr>
<td>Title</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pathophysiological changes after vaccination:</td>
</tr>
<tr>
<td>Symptomology following mRNA vaccination:</td>
</tr>
<tr>
<td>Symptomology following mRNA vaccination:</td>
</tr>
<tr>
<td>Immune mediate events associated with COVOD-19 disease, a review of Slovenia data:</td>
</tr>
<tr>
<td>Concerns for Pfizer vaccine failure to wildtype variants after Delta and vaccine induced enhanced illness, as demonstrated in a mice model:</td>
</tr>
<tr>
<td>Concerns about the lipid nanoparticle in the mRNA contributing to adverse reactions:</td>
</tr>
</tbody>
</table>

Covid-19 Vaccine Injuries — Preventing Inequities in Compensation
The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory: https://pubmed.ncbi.nlm.nih.gov/34841223/